-
公开(公告)号：US11046785B2
公开(公告)日：2021-06-29
申请号：US16541743
申请日：2019-08-15
Applicant: Dyax Corp.
Inventor： Gregory P. Conley , Andrew Nixon , Daniel J. Sexton
Abstract: Disclosed herein are compositions comprising one or more antibodies that specifically bind active plasma kallikrein (e.g., human plasma kallikrein) and methods of using such compositions for the treatment of retinal diseases, such as diabetic macular edema.
-
Patent Agency Ranking
公开(公告)号：US20150362493A1
公开(公告)日：2015-12-17
申请号：US14761690
申请日：2014-01-17
Applicant: DYAX CORP.
Inventor： Daniel J. Sexton , Ryan Faucette , Jon A. Kenniston , Gregory P. Conley , Andrew Nixon , Christopher TenHoor , Burt Adelman , Yung Chyung
IPC: G01N33/573 , C07K7/06 , C07K16/40
CPC classification number: G01N33/5735 , C07K7/06 , C07K16/36 , C07K16/40 , C07K2317/21 , C07K2317/76 , G01N2333/745 , G01N2800/065 , G01N2800/102 , G01N2800/52 , G01N2800/70
Abstract: The present disclosure provides methods of evaluating a subject, e.g., a subject at risk for or suffering from a pKal-mediated or bradykinin-mediated disorder, based on values (e.g., percentages) of intact and/or cleaved kininogen in a sample of the subject. Provided methods permit analysis of patients with plasma kallikrein-mediated angioedema (KMA), or other diseases mediated by pKal useful in the evaluation and treatment. Such methods can involve the use of a detection agent that preferentially binds cleaved kininogen or intact kininogen.
Abstract translation: 本公开提供了评估受试者的方法，例如，基于pKal介导的或缓激肽介导的病症的风险或患有pKal介导的或缓激肽介导的病症的受试者，基于样品中完整和/或切割的激肽原的值（例如，百分比） 学科。 提供的方法允许对血浆激肽释放酶介导的血管性水肿（KMA）或由pKal介导的其它疾病的患者进行分析，其可用于评估和治疗。 这样的方法可以涉及使用优先结合切割的激肽原或完整激肽原的检测剂。
-
公开(公告)号：US20180118851A1
公开(公告)日：2018-05-03
申请号：US15541066
申请日：2015-12-31
Applicant: Dyax Corp.
Inventor： Stephen R. Comeau , Andrew Nixon , Niksa Kastrapeli , Jon A. Kenniston , Gregory P. Conley , Shauna Mason , Allison P. Lindberg , Kristopher Kopacz , Burt Adelman
IPC: C07K16/40 , C07K16/36 , C12N9/64 , A61K39/395
CPC classification number: C07K16/40 , A61K39/395 , A61P7/02 , C07K16/36 , C07K2317/31 , C07K2317/51 , C07K2317/622 , C07K2317/64 , C07K2317/76 , C07K2317/94 , C12N9/64
Abstract: Described herein are bispecific antibodies that bind to plasma kallikrein (pKal) and Factor XII and methods of producing and using such bi-specific antibodies for treating diseases or disorders associated with the contact system, e.g., hereditary angioedema or thrombosis. One aspect of the present disclosure is a bispecific antibody, comprising: a first polypeptide that comprises a light chain of a first antibody, the light chain comprising a light chain variable region (VL) and a light chain constant region (CL) (e.g., a kappa light chain or a lambda light chain); and a second polypeptide that comprises a heavy chain of the first antibody, the heavy chain comprising a heavy chain variable region (VH) and a heavy chain constant region (CH).
-
公开(公告)号：US20150274841A1
公开(公告)日：2015-10-01
申请号：US14669607
申请日：2015-03-26
Applicant: Dyax Corp.
Inventor： Gregory P. Conley , Andrew Nixon , Daniel J. Sexton
CPC classification number: C07K16/40 , A61K9/0051 , A61K2039/505 , C07K2317/30 , C07K2317/55 , C07K2317/76 , C07K2317/92
Abstract: Disclosed herein are compositions comprising one or more antibodies that specifically bind active plasma kallikrein (e.g., human plasma kallikrein) and methods of using such compositions for the treatment of retinal diseases, such as diabetic macular edema.
Abstract translation: 本文公开了包含一种或多种特异性结合活性血浆激肽释放酶（例如人血浆激肽释放酶）的抗体的组合物以及使用该组合物治疗视网膜疾病如糖尿病性黄斑水肿的方法。
-
公开(公告)号：US10428158B2
公开(公告)日：2019-10-01
申请号：US14669607
申请日：2015-03-26
Applicant: Dyax Corp.
Inventor： Gregory P. Conley , Andrew Nixon , Daniel J. Sexton
Abstract: Disclosed herein are compositions comprising one or more antibodies that specifically bind active plasma kallikrein (e.g., human plasma kallikrein) and methods of using such compositions for the treatment of retinal diseases, such as diabetic macular edema.
-
6.发明申请公开(公告)号：US20160252527A1
公开(公告)日：2016-09-01
申请号：US15030811
申请日：2014-10-17
Applicant: DYAX CORP.
Inventor： Daniel J. Sexton , Ryan Faucette , Jon A. Kenniston , Gregory P. Conley , Andrew Nixon , Christopher TenHoor , Burt Adelman
CPC classification number: G01N33/6893 , A61K2039/505 , C07K16/36 , C07K16/40 , C07K2317/76 , C12Q1/37 , C12Q1/56 , C12Y304/21034 , C12Y304/21038 , G01N2333/4713 , G01N2333/96455 , G01N2333/96458 , G01N2500/02 , G01N2500/20 , G01N2800/224 , G01N2800/50 , G01N2800/52
Abstract: Methods and assays for determining the activation level of the plasma kallikrein (pKal) system and the uses thereof for assessing the activity of pKal modulators on the pKal system.
Abstract translation: 用于确定血浆激肽释放酶（pKal）系统的激活水平的方法和测定及其用于评估pKal系统上pKal调节剂活性的用途。
-
-
-
-
-
Search Results
6
records
(took 0.012 seconds)
